Table 3.
Summary of efficacy of lenvatinib post immunotherapy in retrospective cohorts
Study | Objective response rate | Disease control rate | Median PFS (months) | Median OS (months) |
---|---|---|---|---|
Gile et al.31 | Not provided | Not provided | 4 | 13 |
Yoo et al.30 | 3 (15.8) | 12 (63.2) | 6.1 | 11.2 |
Values are presented as number or number (%).
PFS, progression-free survival; OS, overall survival.